Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection. Their findings were published in the June 2 issue of Nature Medicine [10.1038/s41591-026-04442-2]. Recurrent C. difficile infection is a serious and often debilitating condition that can occur after antibiotic treatment disrupts the natural balance of bacteria in the gut. Although fecal microbiota transplants (FMT)—a treatment that transfers stool from healthy donors to restore gut bacteria in patients with severe or recurrent infections—have proven effective for many patients, more standardized and scalable therapeutic options are needed.